Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PSPA
MCID: PTT048
MIFTS: 65

Pituitary Adenoma, Prolactin-Secreting (PSPA)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pituitary Adenoma, Prolactin-Secreting

About this section

MalaCards integrated aliases for Pituitary Adenoma, Prolactin-Secreting:

Name: Pituitary Adenoma, Prolactin-Secreting 56 12 13
Prolactinoma 12 52 58 73 54 43 15 71
Prolactin-Producing Pituitary Gland Adenoma 52 29 6 17
Prolactin-Secreting Pituitary Adenoma 52 58 73
Prl-Secreting Pituitary Adenoma 52 58
Pituitary Lactotrophic Adenoma 52 58
Lactotroph Adenoma 52 58
Prloma 52 58
Prolactinoma of Pituitary Gland 12
Prolactinoma, Familial 56
Familial Prolactinoma 12
Pspa 73

Characteristics:

Orphanet epidemiological data:

58
prolactinoma
Inheritance: Not applicable; Prevalence: 1-5/10000 (United Kingdom),6-9/10000 (Belgium),1-5/10000 (Switzerland),1-9/100000 (Malta); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

OMIM:

56
Inheritance:
familial tendency independent of association with men-1


Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Reproductive diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare infertility disorders
Rare endocrine diseases


Sources

Summaries for Pituitary Adenoma, Prolactin-Secreting

About this section
NIH Rare Diseases : 52 Prolactinoma is a tumor of the pituitary gland that causes increased levels of the hormone prolactin . This hormone normally stimulates breast development and milk production in women. Prolactinoma can affect men or women. In women, the symptoms may include unusual milk production (galactorrhea) when not pregnant or nursing and having no menstrual cycles (amenorrhea ). In men, the most common symptoms are decreased sex drive and infertility. Most prolactinomas occur by chance (sporadically) in people with no family history . In a small number of cases, prolactinoma may be caused by a genetic condition such as multiple endocrine neoplasia type 1 (MEN1) or familial isolated pituitary adenoma . Treatment for prolactinoma usually involves taking oral medications known as dopamine agonists. These medications can reduce prolactin levels and shrink the tumor. In more severe cases, radiation therapy or surgery may be needed.

MalaCards based summary : Pituitary Adenoma, Prolactin-Secreting, also known as prolactinoma, is related to prolactin producing pituitary tumor and amenorrhea. An important gene associated with Pituitary Adenoma, Prolactin-Secreting is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Quinagolide and Cardiotonic Agents have been mentioned in the context of this disorder. Affiliated tissues include pituitary, breast and testes, and related phenotypes are impotence and galactorrhea

OMIM : 56 Prolactin-secreting pituitary adenoma, or prolactinoma, is the most common type of hormonally active pituitary adenoma. These tumors can also be seen as a feature of multiple endocrine neoplasia type I (MEN1; 131100). See also 102200 for a discussion of familial isolated pituitary adenoma (FIPA) and acromegaly due to a growth hormone (GH; 139250)-secreting pituitary adenoma, which are also caused by mutation in the AIP gene. Schlechte (2003) discussed prolactinoma in general terms as a clinical, diagnostic, and therapeutic problem. (600634)

UniProtKB/Swiss-Prot : 73 Prolactin-secreting pituitary adenoma: Most common type of hormonally active pituitary adenoma.

Sources

Related Diseases for Pituitary Adenoma, Prolactin-Secreting

About this section

Diseases related to Pituitary Adenoma, Prolactin-Secreting via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 424)
# Related Disease Score Top Affiliating Genes
1 prolactin producing pituitary tumor 32.9 PRL POMC DRD2
2 amenorrhea 31.7 TRH PRL POMC IGF1
3 diabetes insipidus 31.4 PRL POMC GH1
4 pituitary tumors 31.4 SSTR5 SST PTTG1 PRL POMC MEN1
5 hypopituitarism 31.3 TRH PRL POU1F1 POMC IGF1 GH1
6 sexual disorder 31.3 PRL POMC IGF1 DRD2
7 hyperparathyroidism 31.2 PRKAR1A MEN1 IGF1
8 gynecomastia 31.2 PRL POMC DRD2
9 gigantism 31.1 PRL GH1 AIP
10 multiple endocrine neoplasia, type i 31.1 SST PRL PRKAR1A POMC MEN1 GNAS
11 empty sella syndrome 31.1 TRH PRL POMC IGF1 GH1
12 galactorrhea 31.1 PRL IGF1 DRD2
13 pituitary apoplexy 31.1 TRH SST PRL POMC MEN1 IGF1
14 chromophobe adenoma 31.1 TRH PRL POMC GH1
15 insulin-like growth factor i 31.0 PRL IGF1 GH1
16 intracranial hypertension, idiopathic 31.0 SSTR1 POMC IGF1 GH1
17 anovulation 31.0 PRL IGF1 DRD2
18 non-functioning pituitary adenoma 30.9 SST GH1
19 hypothyroidism 30.9 TRH SST PRL POU1F1 POMC IGF1
20 primary hyperparathyroidism 30.9 PRL PRKAR1A POMC MEN1 IGF1
21 parathyroid adenoma 30.8 PRKAR1A MEN1 IGF1 GNAS
22 insulinoma 30.8 SSTR5 SSTR2 SST MEN1
23 hypoglycemia 30.7 SST PRL POMC IGF1 GH1
24 familial isolated pituitary adenoma 30.7 MEN1 CDH23 AIP
25 pituitary carcinoma 30.7 SSTR2 SST PTTG1 PRL POMC MEN1
26 craniopharyngioma 30.6 TRH PTTG1 PRL POU1F1 IGF1 GH1
27 goiter 30.6 TRH SST PRL IGF1 GNAS
28 hyperandrogenism 30.6 PRL POMC IGF1 GH1
29 turner syndrome 30.6 PRL POMC IGF1 GH1
30 pituitary hormone deficiency, combined, 2 30.6 TRH PRL POU1F1 POMC IGF1 GH1
31 lymphocytic hypophysitis 30.6 POMC GH1
32 schizoaffective disorder 30.6 SST PRL DRD2
33 carcinoid syndrome 30.5 SST MEN1 IGF1
34 hyperprolactinemia 30.5 TRH SST PRL POMC IGF1 GNAS
35 thyroid gland disease 30.5 TRH SST PRL POMC IGF1 GNAS
36 adrenal cortical adenoma 30.5 PRKAR1A POMC MEN1
37 gastrinoma 30.4 SSTR5 SSTR2 SSTR1 SST POMC MEN1
38 personality disorder 30.4 SST PRL DRD2
39 diabetes insipidus, neurohypophyseal 30.4 TRH PRL POMC IGF1
40 hypothyroidism, congenital, nongoitrous, 4 30.4 PRL POU1F1 POMC GH1
41 sleep disorder 30.4 PRL POMC IGF1 DRD2
42 adenoma 30.4 TRH SSTR5 SSTR2 SST PTTG1 PRL
43 hyperthyroidism 30.4 TRH SST PRL POMC IGF1 GNAS
44 abducens nerve disease 30.4 PRL POMC
45 adrenal adenoma 30.4 PRKAR1A POMC MEN1 GNAS
46 polycystic ovary syndrome 30.3 PRL POMC IGF1 GH1
47 pituitary adenoma 1, multiple types 30.3 SST PRL MEN1 IGF1 GH1 AIP
48 mccune-albright syndrome 30.3 SST PRL PRKAR1A MEN1 IGF1 GNAS
49 fibrous dysplasia 30.3 SST PRL IGF1 GNAS GH1
50 pseudohypoparathyroidism 30.2 TRH PRL PRKAR1A IGF1 GNAS

Graphical network of the top 20 diseases related to Pituitary Adenoma, Prolactin-Secreting:



Diseases related to Pituitary Adenoma, Prolactin-Secreting
Sources

Symptoms & Phenotypes for Pituitary Adenoma, Prolactin-Secreting

About this section

Human phenotypes related to Pituitary Adenoma, Prolactin-Secreting:

58 31 (show top 50) (show all 56)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 impotence 58 31 hallmark (90%) Very frequent (99-80%) HP:0000802
2 galactorrhea 58 31 hallmark (90%) Very frequent (99-80%) HP:0100829
3 decreased fertility in males 58 31 hallmark (90%) Very frequent (99-80%) HP:0012041
4 male hypogonadism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000026
5 irregular menstruation 58 31 hallmark (90%) Very frequent (99-80%) HP:0000858
6 amenorrhea 58 31 hallmark (90%) Very frequent (99-80%) HP:0000141
7 decreased fertility in females 58 31 hallmark (90%) Very frequent (99-80%) HP:0000868
8 female hypogonadism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000134
9 decreased female libido 58 31 hallmark (90%) Very frequent (99-80%) HP:0030018
10 hypogonadotropic hypogonadism 31 hallmark (90%) HP:0000044
11 vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002013
12 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
13 progressive visual loss 58 31 frequent (33%) Frequent (79-30%) HP:0000529
14 osteopenia 58 31 frequent (33%) Frequent (79-30%) HP:0000938
15 osteoporosis 58 31 frequent (33%) Frequent (79-30%) HP:0000939
16 pallor 58 31 frequent (33%) Frequent (79-30%) HP:0000980
17 easy fatigability 58 31 frequent (33%) Frequent (79-30%) HP:0003388
18 gynecomastia 58 31 frequent (33%) Frequent (79-30%) HP:0000771
19 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
20 dyspareunia 58 31 frequent (33%) Frequent (79-30%) HP:0030016
21 hypotension 58 31 frequent (33%) Frequent (79-30%) HP:0002615
22 pituitary hypothyroidism 58 31 frequent (33%) Frequent (79-30%) HP:0008245
23 adrenocorticotropic hormone deficiency 58 31 frequent (33%) Frequent (79-30%) HP:0011748
24 decreased circulating acth level 58 31 frequent (33%) Frequent (79-30%) HP:0002920
25 secondary growth hormone deficiency 58 31 frequent (33%) Frequent (79-30%) HP:0008240
26 adrenocorticotropin deficient adrenal insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0011735
27 abnormal hair quantity 31 frequent (33%) HP:0011362
28 blindness 58 31 occasional (7.5%) Occasional (29-5%) HP:0000618
29 delayed puberty 58 31 occasional (7.5%) Occasional (29-5%) HP:0000823
30 ptosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000508
31 vertigo 58 31 occasional (7.5%) Occasional (29-5%) HP:0002321
32 growth hormone excess 58 31 occasional (7.5%) Occasional (29-5%) HP:0000845
33 diplopia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000651
34 oculomotor nerve palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0012246
35 sudden loss of visual acuity 58 31 occasional (7.5%) Occasional (29-5%) HP:0001117
36 cranial nerve vi palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0006897
37 fourth cranial nerve palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0007011
38 internal ophthalmoplegia 58 31 occasional (7.5%) Occasional (29-5%) HP:0007942
39 bitemporal hemianopia 58 31 occasional (7.5%) Occasional (29-5%) HP:0030521
40 seizure 31 occasional (7.5%) HP:0001250
41 seizures 58 Occasional (29-5%)
42 cranial nerve paralysis 58 Occasional (29-5%)
43 nausea and vomiting 58 Frequent (79-30%)
44 erectile abnormalities 58 Very frequent (99-80%)
45 hypogonadotrophic hypogonadism 58 Very frequent (99-80%)
46 anterior hypopituitarism 58 Occasional (29-5%)
47 abnormality of the menstrual cycle 58 Very frequent (99-80%)
48 pituitary prolactin cell adenoma 31 HP:0006767
49 hypogonadism 58 Very frequent (99-80%)
50 hemianopia 58 Occasional (29-5%)

Symptoms via clinical synopsis from OMIM:

56
Oncology:
prolactinoma
prolactin-secreting pituitary adenoma

Clinical features from OMIM:

600634

GenomeRNAi Phenotypes related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.72 MEN1
2 Decreased viability GR00221-A-1 9.72 PRKAR1A
3 Decreased viability GR00221-A-2 9.72 PRKAR1A
4 Decreased viability GR00221-A-3 9.72 PRKAR1A
5 Decreased viability GR00221-A-4 9.72 PRKAR1A
6 Decreased viability GR00240-S-1 9.72 AIP CORT SST
7 Decreased viability GR00249-S 9.72 GH1 SSTR2 SSTR4 SSTR5
8 Decreased viability GR00381-A-1 9.72 CORT GNAS SSTR3 SSTR5
9 Decreased viability GR00381-A-2 9.72 CORT
10 Decreased viability GR00381-A-3 9.72 CORT
11 Decreased viability GR00386-A-1 9.72 CORT GNAS POMC TRH
12 Decreased viability GR00402-S-2 9.72 CORT SSTR3 SSTR5

MGI Mouse Phenotypes related to Pituitary Adenoma, Prolactin-Secreting:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 CDH23 CORT DRD2 GNAS POMC PRKAR1A
2 homeostasis/metabolism MP:0005376 10.36 AIP CDH23 CORT DRD2 GNAS IGF1
3 growth/size/body region MP:0005378 10.28 AIP CDH23 CORT DRD2 GNAS IGF1
4 endocrine/exocrine gland MP:0005379 10.27 AIP CORT DRD2 GNAS IGF1 MEN1
5 cellular MP:0005384 10.22 AIP CDH23 DRD2 GNAS IGF1 MEN1
6 cardiovascular system MP:0005385 10.19 AIP DRD2 GNAS IGF1 MEN1 POMC
7 immune system MP:0005387 10.15 CDH23 DRD2 GNAS IGF1 MEN1 POMC
8 adipose tissue MP:0005375 10.07 CDH23 DRD2 GNAS IGF1 POMC PRKAR1A
9 nervous system MP:0003631 9.97 CDH23 DRD2 GNAS IGF1 MEN1 POMC
10 liver/biliary system MP:0005370 9.87 AIP DRD2 GNAS MEN1 POMC PRKAR1A
11 neoplasm MP:0002006 9.86 AIP DRD2 GNAS IGF1 MEN1 POMC
12 no phenotypic analysis MP:0003012 9.56 DRD2 GNAS POMC PTTG1 SST SSTR3
13 skeleton MP:0005390 9.28 CDH23 DRD2 GNAS IGF1 POU1F1 PRKAR1A
Sources

Drugs & Therapeutics for Pituitary Adenoma, Prolactin-Secreting

About this section

Drugs for Pituitary Adenoma, Prolactin-Secreting (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
2 Cardiotonic Agents Phase 4
3 Sympathomimetics Phase 4
4 Protective Agents Phase 4
5
Cabergoline Approved Phase 2, Phase 3 81409-90-7 54746
6
Pasireotide Approved Phase 2, Phase 3 396091-73-9 9941444
7
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
8 Dopamine agonists Phase 2, Phase 3
9 Antiparkinson Agents Phase 2, Phase 3
10
Bromocriptine Approved, Investigational Phase 2 25614-03-3 31101
11
Sodium citrate Approved, Investigational Phase 2 68-04-2
12
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
13
Ropinirole Approved, Investigational Phase 1, Phase 2 91374-20-8, 91374-21-9 497540 5095
14
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
15
Enclomiphene Investigational Phase 2 15690-57-0
16 Citrate Phase 2
17 Estrogen Receptor Antagonists Phase 2
18 Clomiphene Phase 2
19 Estrogen Receptor Modulators Phase 2
20 Estrogen Antagonists Phase 2
21 Estrogens Phase 2
22 Zuclomiphene Phase 2
23 Protein Kinase Inhibitors Phase 2
24
Curcumin Approved, Experimental, Investigational Phase 1 458-37-7 969516
25
Turmeric Approved, Experimental, Investigational Phase 1
26
leucovorin Approved Phase 1 58-05-9 6006 143
27
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3
28
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
29
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
30 Analgesics, Non-Narcotic Phase 1
31 Analgesics Phase 1
32 Antirheumatic Agents Phase 1
33 Turmeric extract Phase 1
34 Anti-Inflammatory Agents, Non-Steroidal Phase 1
35 Hormones Phase 1
36 Anti-Inflammatory Agents Phase 1
37 Hormone Antagonists Phase 1
38 Vitamin B Complex Phase 1
39 Folate Phase 1
40 Vitamin B9 Phase 1
41 Gastrointestinal Agents Phase 1
42 Antineoplastic Agents, Hormonal Phase 1
43 Antiemetics Phase 1
44 glucocorticoids Phase 1
45 BB 1101 Phase 1
46
Cosyntropin Approved 16960-16-0 16129617
47
Dopamine Approved 51-61-6, 62-31-7 681
48
Metronidazole Approved 443-48-1 4173
49
chloroquine Approved, Investigational, Vet_approved 54-05-7 2719
50
Hydroxychloroquine Approved 118-42-3 3652

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
2 PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials Recruiting NCT04107480 Phase 4 Dopamine Agonists
3 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
4 Recovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent Hypogonadism Completed NCT00697814 Phase 2 Clomiphene citrate
5 Bromocriptine Quick Release (QR) as Adjunct Therapy in Type 1 Diabetes Completed NCT02544321 Phase 2 Bromocriptine
6 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
7 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability Active, not recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
8 Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients Unknown status NCT01344291 Phase 1 Curcumin
9 A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma Terminated NCT02629549 Phase 1 OTL38
10 A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
11 Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma Unknown status NCT00598949
12 Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus Unknown status NCT02536261
13 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332
14 Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. Unknown status NCT01143584 Cabergoline;cabergoline
15 Insulin Resistance and Lipid Profile in Non-Obese Women With Prolactinoma Treated With Dopamine Agonists Completed NCT00481299
16 Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study Completed NCT01504399
17 Observational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With Cabergoline Completed NCT00460616 Cabergoline
18 The Value of 25 mcg Cortrosyn Stimulation Test to Assess Adult HPA Axis Completed NCT01428336
19 Prospective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive Prolactinoma Recruiting NCT03353025 dopamine agonist treatment
20 Validation of a Novel Patient-Reported Quality of Life Metric "Prolac-10" for Patients Undergoing Medical Therapy for Prolactinoma Recruiting NCT04106531
21 Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma: A Prospective, Randomized, Open Label, Active-controlled, Clinical Trial Recruiting NCT03457389 Cabergoline
22 PITUItary Carcinomas or Aggressive Tumors REgistry: Monocentric Study Form a Cohort of Patient Operated on for Pituitary Tumors in University Hospital of Lyon (France) Recruiting NCT02854228
23 KRANIOPHARYNGEOM Registry 2019 Multicenter Registry for Patients With Childhood-onset Craniopharyngioma, Xanthogranuloma, Cysts of Rathke's Pouch, Meningioma, Pituitary Adenoma, Arachnoid Cysts Recruiting NCT04158284
24 Seoul National University Pituitary Disease Cohort Study Recruiting NCT03474601
25 A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related Disorders Recruiting NCT00001595
26 Molecular Imaging of Pituitary Adenomas Recruiting NCT03815838
27 Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA Recruiting NCT00461188
28 Long Term Outcome Study in Patients With Pituitary Disorders Active, not recruiting NCT03665064
29 Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) Active, not recruiting NCT03043508
30 The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of of Prolactinomas. Not yet recruiting NCT03717454 Drug treatment
31 The Effect of Combined Treatment of Cabergoline With Hydroxychloroquine/Chloroquine for Resistant Prolactinomas Not yet recruiting NCT03400865 HCQ/CQ and CAB combined treatment
32 The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of Nonfunctioning Pituitary Adenoma Not yet recruiting NCT03714763 Drug treatment
33 Epidemiology of Pituitary Tumours: Prevalence of Associated Endocrine and Non-endocrine Tumours and Potential Implications in the Management and Follow-up of Patients" Not yet recruiting NCT03973450

Search NIH Clinical Center for Pituitary Adenoma, Prolactin-Secreting

Cochrane evidence based reviews: prolactinoma

Sources

Genetic Tests for Pituitary Adenoma, Prolactin-Secreting

About this section

Genetic tests related to Pituitary Adenoma, Prolactin-Secreting:

# Genetic test Affiliating Genes
1 Prolactin-Producing Pituitary Gland Adenoma 29
Sources

Anatomical Context for Pituitary Adenoma, Prolactin-Secreting

About this section

MalaCards organs/tissues related to Pituitary Adenoma, Prolactin-Secreting:

40
Pituitary, Breast, Testes, Bone, Thyroid, Brain, Heart
Sources

Publications for Pituitary Adenoma, Prolactin-Secreting

About this section

Articles related to Pituitary Adenoma, Prolactin-Secreting:

(show top 50) (show all 2180)
# Title Authors PMID Year
1
AIP Familial Isolated Pituitary Adenomas 6 61
22720333 2012
2
Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. 56 54
17244780 2007
3
Clinical practice. Prolactinoma. 61 56
14627789 2003
4
Familial prolactinoma. 56 61
7621566 1995
5
Pituitary adenoma predisposition caused by germline mutations in the AIP gene. 56
16728643 2006
6
Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. 54 61
20130078 2010
7
Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. 61 54
19890024 2010
8
Proteomic analysis of prolactinoma cells by immuno-laser capture microdissection combined with online two-dimensional nano-scale liquid chromatography/mass spectrometry. 61 54
20205839 2010
9
The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders. 54 61
19905999 2009
10
Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. 61 54
19509108 2009
11
An Intronic mutation is associated with prolactinoma in a young boy, decreased penetrance in his large family, and variable effects on MEN1 mRNA and protein. 61 54
19391077 2009
12
Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism. 54 61
19675520 2009
13
Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. 61 54
18791324 2009
14
Endocrine actions of cortistatin: in vivo studies. 54 61
18281148 2008
15
Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. 61 54
18426817 2008
16
Growth hormone producing prolactinoma in juvenile cystinosis: a simple coincidence? 61 54
17638022 2008
17
Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. 61 54
17540335 2007
18
Giant prolactinomas in adolescence: an uncommon cause of blindness. 61 54
16983572 2007
19
What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. 61 54
17287403 2007
20
PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes. 54 61
17222350 2007
21
[IGF-1 plasma levels evaluation in prolactinoma]. 54 61
17057896 2006
22
Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'. 61 54
16598425 2006
23
Application of new homologous in vitro bioassays for human lactogens to assess the actual bioactivity of human prolactin isoforms in hyperprolactinaemic patients. 61 54
16886952 2006
24
Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma. 54 61
16449338 2006
25
Bone morphogenetic protein-4 control of pituitary pathophysiology. 61 54
16809920 2006
26
Genesis of prolactinomas: studies using estrogen-treated animals. 61 54
16809921 2006
27
A case of macroprolactinoma and elevated insulin-like growth factor-I in a young boy. 54 61
16421054 2005
28
Treatment of pituitary tumors: dopamine agonists. 61 54
16311416 2005
29
Hypercalcemia and local production of parathyroid hormone-related protein by a perisellar rhabdomyosarcoma after remote pituitary irradiation. 61 54
16239205 2005
30
Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour. 61 54
16411064 2005
31
[The best approach to treat prolactinoma]. 54 61
15559242 2004
32
Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. 61 54
15181056 2004
33
Immunolocalization of Pit-1 in gonadotroph nuclei is indicative of the transdifferentiation of gonadotroph to lactotroph cells in prolactinomas induced by estrogen. 61 54
15221415 2004
34
The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. 54 61
15070915 2004
35
Nerve growth factor restores p53 function in pituitary tumor cell lines via trkA-mediated activation of phosphatidylinositol 3-kinase. 61 54
14525955 2004
36
Somatostatin receptors in pituitary function, diagnosis and therapy. 61 54
15281350 2004
37
Diagnosis and management of pituitary tumors: recent advances. 61 54
15024895 2003
38
Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development. 61 54
12972179 2003
39
Gene expression study of thyrotropin releasing hormone (TRH) receptor using RT-PCR: relationship to clinical and immunohistochemical phenotypes in a series of human pituitary adenomas. 61 54
14599121 2003
40
Integrating systemic information at the molecular level: cross-talk between steroid receptors and cytokine signaling on different target cells. 54 61
12794059 2003
41
Macroprolactinaemia associated with prolactin adenoma. 61 54
12660284 2003
42
Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression. 61 54
12554778 2003
43
[The role of somatostatin analogues in the treatment of hypophyseal adenomas]. 54 61
12621362 2003
44
Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells. 61 54
12574225 2003
45
Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. 61 54
12552124 2003
46
Evaluation of endocrine tests. A: the TRH test in patients with hyperprolactinaemia. 54 61
12735420 2003
47
[New mechanisms involved in the pathogenesis of pituitary adenomas]. 61 54
12793085 2003
48
The multiple endocrine neoplasia type 1 gene product, menin, inhibits the human prolactin promoter activity. 61 54
12459032 2002
49
Role of E-cadherin, alpha-, beta-, and gamma-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior. 61 54
12481018 2002
50
"Hook effect" in prolactinomas: case report and review of literature. 61 54
12173917 2002
Sources

Variations for Pituitary Adenoma, Prolactin-Secreting

About this section

ClinVar genetic disease variations for Pituitary Adenoma, Prolactin-Secreting:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 LRP2 NM_004525.3(LRP2):c.13753C>T (p.Arg4585Ter)SNV Likely pathogenic 374076 rs202057289 2:169985570-169985570 2:169129060-169129060

Cosmic variations for Pituitary Adenoma, Prolactin-Secreting:

9 (show top 50) (show all 59)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87132301 PIK3CA pituitary,NS,adenoma,PRL c.1624G>A p.E542K 3:179218294-179218294 30
2 COSM87132318 PIK3CA pituitary,NS,adenoma,PRL c.3073A>G p.T1025A 3:179234230-179234230 30
3 COSM112988978 HRAS pituitary,NS,adenoma,PRL c.34G>C p.G12R 11:534289-534289 30
4 COSM112988917 HRAS pituitary,NS,adenoma,GH c.35G>T p.G12V 11:534288-534288 30
5 COSM93760866 GNAS pituitary,NS,adenoma,GH c.2530C>T p.R844C 20:58909365-58909365 30
6 COSM93761460 GNAS pituitary,NS,adenoma,GH c.2609A>T p.Q870L 20:58909541-58909541 30
7 COSM93761837 GNAS pituitary,NS,adenoma,GH c.2609A>G p.Q870R 20:58909541-58909541 30
8 COSM93760887 GNAS pituitary,NS,adenoma,GH c.2531G>A p.R844H 20:58909366-58909366 30
9 COSM93761140 GNAS pituitary,NS,adenoma,GH c.2530C>A p.R844S 20:58909365-58909365 30
10 COSM87642925 pituitary,NS,adenoma,GH c.94-402C>T p.? 20:58909365-58909365 30
11 COSM93086636 pituitary,NS,adenoma,GH c.604C>T p.R202C 20:58909365-58909365 30
12 COSM93726285 pituitary,NS,adenoma,GH c.559C>T p.R187C 20:58909365-58909365 30
13 COSM93726301 pituitary,NS,adenoma,GH c.560G>A p.R187H 20:58909366-58909366 30
14 COSM85346237 pituitary,NS,adenoma,GH c.635A>T p.Q212L 20:58909541-58909541 30
15 COSM85345830 pituitary,NS,adenoma,GH c.556C>T p.R186C 20:58909365-58909365 30
16 COSM93779606 pituitary,NS,adenoma,GH c.2488C>T p.R830C 20:58909365-58909365 30
17 COSM89474843 pituitary,NS,adenoma,GH c.*504C>T p.? 20:58909365-58909365 30
18 COSM93702294 pituitary,NS,adenoma,GH c.680A>T p.Q227L 20:58909541-58909541 30
19 COSM93701960 pituitary,NS,adenoma,GH c.601C>T p.R201C 20:58909365-58909365 30
20 COSM93630265 pituitary,NS,adenoma,GH c.*507C>T p.? 20:58909365-58909365 30
21 COSM85345852 pituitary,NS,adenoma,GH c.557G>A p.R186H 20:58909366-58909366 30
22 COSM87642939 pituitary,NS,adenoma,GH c.94-401G>A p.? 20:58909366-58909366 30
23 COSM93726636 pituitary,NS,adenoma,GH c.638A>T p.Q213L 20:58909541-58909541 30
24 COSM93726530 pituitary,NS,adenoma,GH c.559C>A p.R187S 20:58909365-58909365 30
25 COSM93086945 pituitary,NS,adenoma,GH c.683A>T p.Q228L 20:58909541-58909541 30
26 COSM93779631 pituitary,NS,adenoma,GH c.2489G>A p.R830H 20:58909366-58909366 30
27 COSM93779988 pituitary,NS,adenoma,GH c.2567A>T p.Q856L 20:58909541-58909541 30
28 COSM93780281 pituitary,NS,adenoma,GH c.2567A>G p.Q856R 20:58909541-58909541 30
29 COSM93630681 pituitary,NS,adenoma,GH c.*586A>T p.? 20:58909541-58909541 30
30 COSM87643126 pituitary,NS,adenoma,GH c.94-402C>A p.? 20:58909365-58909365 30
31 COSM101951679 pituitary,NS,adenoma,PRL c.35G>T p.G12V 11:534288-534288 30
32 COSM93702186 pituitary,NS,adenoma,GH c.601C>A p.R201S 20:58909365-58909365 30
33 COSM93086649 pituitary,NS,adenoma,GH c.605G>A p.R202H 20:58909366-58909366 30
34 COSM101967337 pituitary,NS,adenoma,PRL c.35G>T p.G12V 11:534288-534288 30
35 COSM85346567 pituitary,NS,adenoma,GH c.635A>G p.Q212R 20:58909541-58909541 30
36 COSM93701978 pituitary,NS,adenoma,GH c.602G>A p.R201H 20:58909366-58909366 30
37 COSM89475152 pituitary,NS,adenoma,GH c.*504C>A p.? 20:58909365-58909365 30
38 COSM93726964 pituitary,NS,adenoma,GH c.638A>G p.Q213R 20:58909541-58909541 30
39 COSM89474878 pituitary,NS,adenoma,GH c.*505G>A p.? 20:58909366-58909366 30
40 COSM87643479 pituitary,NS,adenoma,GH c.94-226A>G p.? 20:58909541-58909541 30
41 COSM87643227 pituitary,NS,adenoma,GH c.94-226A>T p.? 20:58909541-58909541 30
42 COSM105721467 pituitary,NS,adenoma,PRL c.35G>T p.G12V 11:534288-534288 30
43 COSM93086861 pituitary,NS,adenoma,GH c.604C>A p.R202S 20:58909365-58909365 30
44 COSM93631069 pituitary,NS,adenoma,GH c.*586A>G p.? 20:58909541-58909541 30
45 COSM93630284 pituitary,NS,adenoma,GH c.*508G>A p.? 20:58909366-58909366 30
46 COSM91331236 pituitary,NS,adenoma,GH c.35G>T p.G12V 11:534288-534288 30
47 COSM93087211 pituitary,NS,adenoma,GH c.683A>G p.Q228R 20:58909541-58909541 30
48 COSM93702535 pituitary,NS,adenoma,GH c.680A>G p.Q227R 20:58909541-58909541 30
49 COSM89475620 pituitary,NS,adenoma,GH c.*583A>G p.? 20:58909541-58909541 30
50 COSM89475256 pituitary,NS,adenoma,GH c.*583A>T p.? 20:58909541-58909541 30
Sources

Expression for Pituitary Adenoma, Prolactin-Secreting

About this section
Search GEO for disease gene expression data for Pituitary Adenoma, Prolactin-Secreting.
Sources

Pathways for Pituitary Adenoma, Prolactin-Secreting

About this section

Pathways related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 13.86 TRH SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
2
Peptide ligand-binding receptors 65
Show member pathways
 13.05 TRH SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
3
cAMP signaling pathway 36
12.03 SSTR5 SSTR2 SSTR1 SST POMC GNAS
4
Relaxin signaling pathway 36
Show member pathways
 11.92 SSTR5 SSTR3 SSTR2 SSTR1 SST POU1F1
5
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.88 SSTR2 SSTR1 SST PRKAR1A
6
Glucocorticoid receptor regulatory network 1
11.49 PRL POU1F1 POMC
7
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.73 PRL POMC DRD2
Sources

GO Terms for Pituitary Adenoma, Prolactin-Secreting

About this section

Cellular components related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.02 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1

Biological processes related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.21 TRH SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
2 G protein-coupled receptor signaling pathway GO:0007186 10 TRH SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
3 cell-cell signaling GO:0007267 9.85 TRH SSTR3 SST POMC DRD2
4 forebrain development GO:0030900 9.77 SSTR4 SSTR3 SSTR2 SSTR1 DRD2
5 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.72 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
6 cerebellum development GO:0021549 9.71 SSTR3 SSTR2 SSTR1
7 cellular response to glucocorticoid stimulus GO:0071385 9.71 SSTR5 SSTR4 SSTR3 SSTR2
8 response to starvation GO:0042594 9.69 SSTR3 SSTR2 SSTR1
9 cellular response to estradiol stimulus GO:0071392 9.67 SSTR3 SSTR2 SSTR1
10 positive regulation of multicellular organism growth GO:0040018 9.65 POU1F1 GH1 DRD2
11 neuropeptide signaling pathway GO:0007218 9.63 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 POMC
12 negative regulation of cell proliferation GO:0008285 9.61 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 SST
13 regulation of protein kinase A signaling GO:0010738 9.58 PRKAR1A AIP
14 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.58 PRL GH1
15 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.57 IGF1 GH1
16 peristalsis GO:0030432 9.56 SSTR2 DRD2
17 adenohypophysis development GO:0021984 9.55 POU1F1 DRD2
18 hormone-mediated apoptotic signaling pathway GO:0008628 9.52 SSTR3 SST
19 somatostatin signaling pathway GO:0038170 9.02 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1

Molecular functions related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.88 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 DRD2
2 peptide binding GO:0042277 9.65 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
3 neuropeptide binding GO:0042923 9.55 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
4 G protein-coupled receptor binding GO:0001664 9.54 POMC GNAS CORT
5 hormone activity GO:0005179 9.5 TRH SST PRL POMC IGF1 GH1
6 insulin-like growth factor receptor binding GO:0005159 9.43 IGF1 GNAS
7 prolactin receptor binding GO:0005148 9.32 PRL GH1
8 somatostatin receptor activity GO:0004994 9.02 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
Sources

Sources for Pituitary Adenoma, Prolactin-Secreting

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....